Obstetrics & Gynaecology Search
Obstetrics & Gynaecology Obstetrics & Gynaecology
Most Read Articles
Benralizumab may help reduce OCS reliance in asthma
Roshini Claire Anthony, 18 Mar 2021

Patients with asthma reliant on oral corticosteroids (OCS) may be able to gradually cease or reduce their OCS dose after initiating treatment with benralizumab, according to results of the phase IIIb PONENTE* trial.
RAS inhibitors help prevent adverse cardiovascular outcomes after CABG
6 days ago
Renin-angiotensin system (RAS) inhibitors appear to protect against major adverse cardiovascular events after coronary artery bypass grafting (CABG), whether or not patients had an indication for treatment, a recent study has shown.
Trimetazidine new formulation redefining angina control in daily practice
12 Mar 2021
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Management of MDROs in the ICU and the role of newer antimicrobial agents
Prof. David Paterson, 30 Mar 2021
Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.

Product Highlight - Evenity

31 Mar 2021
Active ingredient: Romosozumab solution for injection 105 mg/ 1.17 mL (90 mg/mL) in prefilled syringes
Presentation: Solution for injection (prefilled syringe) 105 mg/ 1.17 mL (clear to opalescent, colorless to light yellow solution) x 2’s.
Indication: EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Related MIMS Drugs

EVENITY
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Benralizumab may help reduce OCS reliance in asthma
Roshini Claire Anthony, 18 Mar 2021

Patients with asthma reliant on oral corticosteroids (OCS) may be able to gradually cease or reduce their OCS dose after initiating treatment with benralizumab, according to results of the phase IIIb PONENTE* trial.
RAS inhibitors help prevent adverse cardiovascular outcomes after CABG
6 days ago
Renin-angiotensin system (RAS) inhibitors appear to protect against major adverse cardiovascular events after coronary artery bypass grafting (CABG), whether or not patients had an indication for treatment, a recent study has shown.
Trimetazidine new formulation redefining angina control in daily practice
12 Mar 2021
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Management of MDROs in the ICU and the role of newer antimicrobial agents
Prof. David Paterson, 30 Mar 2021
Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.